Does Long-Term Acyclovir Harm the Liver?
Long-term acyclovir use, typically for chronic herpes suppression at doses of 400 mg twice daily, shows no significant impact on liver function in most patients. Clinical studies and post-marketing data report rare cases of transient liver enzyme elevations (ALT/AST), but these usually resolve without stopping the drug and do not progress to serious injury.[1][2]
What Do Studies Show on Liver Enzymes?
In a 12-month trial of 799 patients on suppressive acyclovir (400-800 mg daily), only 1-4% had mild ALT increases, with no cases exceeding 5 times the upper limit of normal. Liver biopsies in affected patients showed no pathology. A 5-year extension study confirmed stable liver function over time.[1] Similar findings appear in HIV patients on long-term therapy, where enzyme rises were comparable to placebo groups.[3]
Who Might Face Liver Risks?
Patients with pre-existing liver disease (e.g., hepatitis B/C) or heavy alcohol use have higher rates of enzyme elevations—up to 10% in some cohorts—but causality is unclear, as herpes reactivation itself stresses the liver. No confirmed cases of acyclovir-induced acute liver failure or cirrhosis link directly to chronic use. Risk factors include high doses (>1g/day) or IV administration, less common in long-term oral therapy.[2][4]
What Happens If Enzymes Rise?
Mild elevations (2-3x normal) often normalize spontaneously. Guidelines recommend monitoring LFTs at baseline and every 3-6 months in at-risk patients, with dose reduction or discontinuation if levels exceed 5x normal or symptoms like jaundice appear. No specific antidote exists; supportive care suffices.[4]
How Does Acyclovir Compare to Alternatives Like Valacyclovir?
Valacyclovir, a prodrug converted to acyclovir, has identical liver safety profile due to the same active metabolite. Famciclovir shows even fewer enzyme changes in head-to-head trials. All three are preferred over older drugs like foscarnet, which carries true hepatotoxicity risks.[1][3]
Regulatory View and Monitoring Advice
FDA labeling notes reversible hepatitis as rare (<1%), with no black-box liver warning. EMA data aligns, emphasizing vigilance in renal impairment (as poor clearance raises systemic exposure). Routine LFTs aren't mandated for healthy patients on suppression therapy.[2]
[1]: Spruance et al., Antimicrob Agents Chemother, 1996
[2]: FDA Acyclovir Label
[3]: Fife et al., J Infect Dis, 1994
[4]: LiverTox: Acyclovir